PACTR202112758618724尚未招募3 期
D3-Penta 21- A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years old
Fondazione Penta Onlus Penta0 个研究点目标入组 370 人开始时间: 2021年12月15日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 370
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 Year(s) 至 5 Year(s)（—）
- 性别
- All
入选标准
- •1. HIV-1 infected children who are virologically suppressed for at least the last 6 months prior to enrolmenta,b
- •2. Aged 2 to <15 years old
- •3. Weight 6 kg or higher
- •4. Children on the same triple-drug PI/r, NNRTI or INSTI containing ART regimen for at least 3 months
- •5. Girls who have reached menarche must have a negative pregnancy test at screening and randomisation
- •6. Girls who are sexually active must be willing to adhere to highly effective methods of contraceptionc
- •7. A parent or legal guardian is willing and able to give informed consent on behalf of the child as per national legislation and willing to adhere to the protocol
- •8. Participant is willing to give informed assent if the trial site clinician deems them old enough and able to understand the age-appropriate information about participation in the study
排除标准
- •1. Any previous switch in ART regimen for virological, immunological or clinical treatment failure
- •2. Any changes in ART in the last 6 months for reasons other than due to child’s growth, drug stock-outs, changes in country guidelines and treatment simplification
- •3. Evidence of previous resistance to 3TC or INSTIa
- •4. Any prior use of regimens consisting of single or dual NRTIs with the exception of a course of zidovudine for PMTCT
- •5. Known allergy or contraindications to dolutegravir or lamivudine
- •6. Diagnosis of tuberculosis and on anti-tuberculosis treatment; children can be enrolled after successful tuberculosis treatmentb
- •7. Treatment of co-morbidities with drugs which have significant interactions with antiretroviral treatment, requiring dose adjustment of the study drugs (children can be enrolled after the illness resolves)
- •8. Randomisation visit more than 12 weeks after the most recent screening visit
- •9. Evidence of hepatitis B infection with no protective immunity against hepatitis B: participants positive for HBsAg or HBcAb and negative for HBsAb?
- •10. Anticipated need for hepatitis C virus therapy with interferon-based regimen prior to the primary endpoint.
- •11. Screening ALT equal to 3 or more times the upper limit of normal AND bilirubin equal to 2 or more times the upper limit of normal (ALT =3xULN AND bilirubin =2xULN)
- •12. Screening ALT equal to 5 or more times the upper limit of normal ALT (=5xULN)
- •13. Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- •14. Screening creatinine clearance <50 mL/min/1.73m2 d
- •15. Patients aged =6 years at moderate or high risk of suicide as determined by Columbia-Suicide Severity Rating Scale (C-SSRS) e
- •16. Girls who are pregnant or breastfeeding
- •17. Children who are in the legal custody of the State and do not have a parent or guardian able to provide informed consent on their behalf.
研究者
相似试验
已完成
不适用
A phase III, randomised, non-inferiority trial, to assess the efficacy and safety of dihydroartemisinin and piperaquine (DHA + PPQ, Artekin®) in comparison with artesunate and mefloquine (AS + MQ) in patients affected by acute, uncomplicated Plasmodium falciparum malariaMalariaISRCTN81306618Sigma-Tau (Italy)1,050
已完成
不适用
A phase III, randomised, non-inferiority trial, to assess the efficacy and safety of Dihydroartemisinin and Piperaquine (DHA + PPQ, Artekin®) in comparison with Artemether and Lumefantrine (A + L, Coartem®) in children with uncomplicated Plasmodium falciparum malariaInfections and InfestationsPlasmodium falciparum malariaMalariaISRCTN16263443Sigma-Tau (Italy)1,500
已完成
3 期
SPIRIT 3: To evaluate the most effective way to use imatinib, nilotinib and ponatinib in the treatment of chronic myeloid leukaemiaChronic myeloid leukaemiaChronic myeloid leukaemia [CML], BCR/ABL-positiveCancerISRCTN60655195ewcastle-upon-Tyne Hospitals NHS Foundation Trust (UK)1,000
进行中（未招募）
1 期
SPIRIT 3 - a phase 3 randomised trial to evaluate the most effective way to use drug treatments in newly diagnosed early stage chronic myeloid leukaemia (cancer of blood which starts in bone marrow) patientsEUCTR2012-005696-14-GBewcastle upon Tyne Hospitals NHS Foundation Trust1,000
招募中
4 期
A comparison of two different durations of the antidote acetylcysteine for paracetamol overdose.ACTRN12616001617459Colin Page220